STX buy signal a huge momentum breaks channel with force. we 75% of probability we will see a bullish trend after pull back
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0510USD
−34.10 MUSD
13.40 MUSD
536.45 M
About SHIELD THERAPEUTICS PLC ORD GBP0.015
Sector
CEO
Gregory Paul Madison
Headquarters
Gateshead Quays
Website
Founded
2015
ISIN
GB00BYV81293
FIGI
BBG00PMLX391
Shield Therapeutics Plc is a commercial stage specialty pharmaceutical company, which engages in addressing iron deficiency with its lead product Accrufer. It operates the Feraccru and PT20 segments. The Feraccru segment refers to the development and commercialization of this product. The PT20 segment related to the development of its secondary asset. The company was founded by Carl Sterritt and Christian Schweiger in 2008 and is headquartered in Gateshead Quays, the United Kingdom.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SHIEF is 0.0220 USD — it has increased by 22.22% in the past 24 hours. Watch Shield Therapeutics PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Shield Therapeutics PLC stocks are traded under the ticker SHIEF.
SHIEF stock has risen by 22.22% compared to the previous week, the last month showed zero change in price, over the last year Shield Therapeutics PLC has showed a 75.56% decrease.
We've gathered analysts' opinions on Shield Therapeutics PLC future price: according to them, SHIEF price has a max estimate of 0.38 USD and a min estimate of 0.03 USD. Watch SHIEF chart and read a more detailed Shield Therapeutics PLC stock forecast: see what analysts think of Shield Therapeutics PLC and suggest that you do with its stocks.
SHIEF reached its all-time high on Dec 6, 2019 with the price of 2.4488 USD, and its all-time low was 0.0135 USD and was reached on Apr 30, 2024. View more price dynamics on SHIEF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SHIEF stock is 18.18% volatile and has beta coefficient of 0.90. Track Shield Therapeutics PLC stock price on the chart and check out the list of the most volatile stocks — is Shield Therapeutics PLC there?
Today Shield Therapeutics PLC has the market capitalization of 18.97 M, it has decreased by 10.40% over the last week.
Yes, you can track Shield Therapeutics PLC financials in yearly and quarterly reports right on TradingView.
Shield Therapeutics PLC is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
SHIEF net income for the last quarter is −21.02 M USD, while the quarter before that showed −12.97 M USD of net income which accounts for −62.00% change. Track more Shield Therapeutics PLC financial stats to get the full picture.
No, SHIEF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Shield Therapeutics PLC EBITDA is −35.45 M USD, and current EBITDA margin is −264.98%. See more stats in Shield Therapeutics PLC financial statements.
Like other stocks, SHIEF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Shield Therapeutics PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Shield Therapeutics PLC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Shield Therapeutics PLC stock shows the sell signal. See more of Shield Therapeutics PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.